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Abstract
The current scenario of in vitro and in vivo diagnostics can be summarized using the “silo metaphor”, where laboratory medicine, pathology and ra-
diology are three conceptually separated diagnostic disciplines, which will increasingly share many comparable features. The substantial progresses 
in our understanding of biochemical-biological interplays that characterize many human diseases, coupled with extraordinary technical advances, 
are now generating important multidisciplinary convergences, leading the way to a new frontier, called integrated diagnostics. This new discipline, 
which is currently defined as convergence of imaging, pathology and laboratory tests with advanced information technology, has an enormous 
potential for revolutionizing diagnosis and therapeutic management of human diseases, including those causing the largest number of worldwide 
deaths (i.e. cardiovascular disease, cancer and infectious diseases). However, some important drawbacks should be overcome, mostly represented 
by insufficient information technology infrastructures, costs and enormous volume of different information that will be integrated and delivered. 
To overcome these hurdles, some specific strategies should be defined and implemented, such as planning major integration of exiting information 
systems or developing innovative ones, combining bioinformatics and imaging informatics, using health technology assessment for assessing cost 
and benefits, providing interpretative comments in integrated reports, developing and using expert systems and neural networks, overcoming cul-
tural and political boundaries for generating multidisciplinary teams and integrated diagnostic algorithms.
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Laboratory diagnostics is conventionally defined 
as a medical science aiming to generate useful 
clinical information by quantifying the concentra-
tion, composition or structure of many different 
analytes in different biological fluids (1). The every-
day activity of laboratory services encompasses 
performing many different tests for generating 
qualitative, semi-quantitative or, most commonly, 
quantitative data. These numbers (alternatively re-
ferred to as “values”) can then be transformed into 
useful medical information by clinical interpreta-
tion, a process developing through experience, 
practice, knowledge and continuous critical analy-
sis, which is actually based on a multifaceted rea-
soning where the different pieces (i.e. demograph-
ical variables, familial and personal history, signs 
and symptoms, results of diagnostic investiga-
tions, comorbidities, treatments) of the intricate 
puzzle (i.e. the patient) are combined (Figu re 1) (2).
There is a long and still unresolved debate regard-
ing how much of the decision-making process can 
be influenced by laboratory testing (3). It is now 
virtually unquestionable that the celebrated “70% 
claim” (i.e. “the clinical laboratory intervenes in 
70% of clinical decision”) is not evidence-based, 
whereby this percentage may be consistently low-
er or higher depending on many variables such as 
the clinical setting, the case-mix, the human ex-
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pertise and skill, and so forth (4,5). Two opposite 
but paradigmatic examples of how heterogene-
ous is the contribution of in vitro diagnostics to 
modern medicine are non-ST elevation myocardial 
infarction (NSTEMI), where the diagnosis can only 
be made with assessment of cardiac troponins, 
versus acute intestinal ischemia, where no single 
diagnostic biomarker achieves sufficient diagnos-
tic accuracy for enabling to make an early and ac-
curate diagnosis (6,7). Irrespective of clinical or en-
vironmental scenario, several lines of evidence 
now attest that the role of the so-called “integrat-
ed diagnostics”, defined as “convergence of imag-
ing, pathology, and laboratory tests with advanced 
information technology (IT)”, will overwhelmingly 
emerge in the foreseeable future, allowing to 
make earlier and more accurate diagnoses, but 
also contributing to save a large amount of human 
and economical resources (Figure 1) (8-10). A bet-
ter comprehension of several biological pathways, 
coupled with emerging technological advances, 
will foster a paradigm shift in the way diagnostics 
has been for long acknowledged, paving the way 
to a new model of healthcare where integration of 
many different data will be more rapid, efficient 
and straightforward, thus enormously amplifying 
the armamentarium that physicians could exploit 
to manage their patients (11).
According to the most recent statistics of the 
World Health Organization (WHO), the three 
worldwide leading causes of death are cardiovas-
cular diseases (17.9 million deaths/year; 31.4% of all 
deaths), cancer (9.0 million deaths/year; 15.8% of 
all deaths) and infectious diseases (5.5 million 
deaths/year; 13.6% of all deaths) (12). Although the 
global mortality for infectious diseases is expected 
to decrease by approximately 30% by the year 
2060, the number of deaths for both cardiovascu-
lar disease and cancer will exhibit a virtually linear 
increase in the next 40 years (Figure 2) (12,13). If di-
agnosis and treatment will not substantially im-
prove, the mortality for these two conditions will 
nearly double by the year 2060. We will hence take 
these three foremost examples, which will contin-
ue to generate the largest clinical, societal and 
economic burden on humanity, for discussing the 
current scenario and the future perspectives of in-
tegrated diagnostics (Table 1).
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Integrated diagnostics in cardiovascular 
disease
The global burden of cardiovascular disease is 
mostly sustained by ischemic heart disease (IHD; 
9.4 million deaths, 52.8% of total cardiovascular 
mortality), followed by stroke (5.8 million deaths, 
32.4% of total cardiovascular mortality, the majori-
ty of which ischemic) and venous thromboembo-
lism (VTE; 1.83 million deaths, 10.2% of total cardi-
ovascular mortality) (13). In all these conditions, 
the role of integrated diagnostics has been clearly 
highlighted. 
Integrated diagnostics in acute myocardial 
infarction
According to the fourth universal definition of my-
ocardial infarction, acute myocardial infarction 
(AMI) is diagnosed in patients with clinical evi-
dence of acute cardiac ischemia, with a rise and/or 
fall of cardiac troponin values and with at least one 
measurement exceeding the 99th percentile of the 
Figure 2. Current World Health Organization data and future 
trends of mortality for cardiovascular disease, cancer and infec-
tious diseases (12).
Disease Laboratory medicine Pathology Radiology Other specific tests
Cardiovascular disease
Acute myocardial 
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resonance angiography
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Sepsis biomarkers, lactate, 
blood culture, serology, 
molecular biology
- Ultrasonography, radiography, computed tomography -
Table 1. Current scenario and future perspectives of using integrated diagnostics for diagnosing the three leading causes of world-
wide mortality
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upper reference limit (URL) (14). This clear-cut defi-
nition poses laboratory diagnostics at the centre 
of the diagnostic reasoning, whereby patients 
with suspected AMI who do not display sugges-
tive values of cardiac troponins will be immediate-
ly and accurately ruled out. On the other hand, 
however, an increased cardiac troponin value is 
not indicative of an ischemic injury, but can be fre-
quently observed in patients with a kaleidoscope 
of non-ischemic cardiac and extra-cardiac pathol-
ogies (6). This clearly implies that cardiac troponins 
have an extraordinarily high negative predictive 
value (NPV) for AMI, up to 99%, but their positive 
predictive value (PPV) is often lower than 50%, 
thus requiring additional elements for value inter-
pretation (6). Although the clinics is always an es-
sential aspect to influence the clinical decision 
making, reliable evidence attests that some radio-
logic tests may provide a very important contribu-
tion to the diagnostic approach of patients with 
heart diseases. 
Coronary angiography has represented for de-
cades the mainstay for identifying and/or localiz-
ing restrictions or obstructions in heart vessels, 
thus enabling the accurate identification of culprit 
lesion(s), prompt establishment of appropriate 
therapeutic measures (e.g. coronary revasculariza-
tion), as well as stratification of short- and long-
term risk of major adverse cardiovascular event 
(MACE), including reinfarction and death (15). The 
combination of coronary angiography and cardiac 
troponin testing seems now virtually unavoidable 
for improving clinical outcomes and reducing 
healthcare costs (16). 
More recently, the fourth universal definition of 
myocardial infarction has first introduced the con-
cept that cardiac magnetic resonance imaging 
(MRI) may be used for more clearly defining the 
aetiology of myocardial injury, thus providing an 
adjunctive and valuable contribution to laboratory 
testing and electrocardiography (14). Interesting 
evidence has then been provided that this tech-
nique may be used for assessing the infarction 
area, alone or in combination with cardiac tro-
ponins (17). Magnetic resonance imaging seems 
especially useful for studying patients with cardiac 
troponin-positive symptoms and unobstructed 
coronaries, in whom an alternative diagnosis could 
be made (e.g. acute or chronic myocarditis, Tako-
Tsubo cardiomyopathy, and so forth) (18).
Interesting evidence is also emerging on the incre-
mental value of combining laboratory and radio-
logy investigations for predicting all-cause and 
cardiovascular death in healthy people. A large 
meta-analysis including five studies and 34,028 
healthy subjects concluded that those with posi-
tive coronary calcium score (i.e. number, areas and 
peak numbers of calcific lesions detectable with 
computed tomography (CT)), have a ~8-fold en-
hanced risk to die during a follow-up of 45 months 
compared to those with negative calcium score 
(odds ratio (OR), 8.43; 95% confidence interval 
(95%CI), 6.25 - 11.36; P < 0.001) (19). Nearly identical 
conclusions were published in another large meta-
analysis, encompassing eight studies and 6521 
type 2 diabetic patients, whereby subjects with 
positive calcium score had ~5 fold higher risk of 
death during a follow-up of 5 years compared to 
those with negative calcium score (relative risk 
(RR), 5.47; 95%CI, 2.59 - 11.53; P < 0.001) (20). Nota-
bly, a recent study published by Korley et al. found 
that the combination of coronary computed to-
mography angiography (CTA) for quantifying cor-
onary artery calcium score with high-sensitivity 
cardiac troponin enables to identify with 100% 
NPV a subset of patients at low risk of MACE (21). 
The validity of this approach has been recently 
confirmed in another study, showing that the ad-
dition of high-sensitivity cardiac troponin tests to 
coronary calcium score significantly improves the 
classification of patients at low and high risk of ob-
structive coronary disease (net reclassification in-
dex, 0.062; 95%CI, 0.035 - 0.089) (22).
Integrated diagnostics in stroke
According to the 2018 guidelines of the American 
Heart Association/American Stroke Association 
(AHA/ASA), the diagnosis of acute ischemic stroke 
(AIS) is made with non-contrast computed tomog-
raphy (NCCT), whilst the use of diffusion-weighted 
MRI (DW-MRI) remains questionable and currently 
limited to patients with negative NCCT findings 
(23). Although the AHA/ASA 2018 guidelines do in-
clude any biomarker in the initial diagnostic ap-
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proach of patients with suspected AIS, evidence 
has been published that some laboratory tests 
may provide a valuable contribution to the diag-
nostic reasoning, especially protein S100B, neu-
ron-specific enolase (NSE), glial fibrillary acidic pro-
tein (GFAP), myelin basic protein (MBP), and D-di-
mer (24). Among these biomarkers, the most solid 
evidence has been garnered for protein S100B. A 
recent meta-analysis concluded that the circulat-
ing values of this protein could be efficiently used 
for differentiating patients with AIS from healthy 
controls (mean difference, 85.5 pg/mL; P < 0.001) 
(25). A previous critical review of the literature also 
highlighted that protein S100B values correlate 
with stroke infarct volume, severity and with func-
tional outcome (26). Therefore, a solid way has 
been paved for evaluating the cost-benefit of a 
possible combination of S100B measurement and 
NCCT in routine diagnostics.
The paradigm of ischemic stroke management lies 
in the straightforward concept that “time is brain”, 
so that treatment shall be started as soon as pos-
sible, preferably within 3 hours according to the 
AHA/ASA guidelines (23,27). Universal agreement 
has been reached that thrombolytic therapy (i.e. 
alteplase) shall not be given to patients with AIS 
displaying platelet count < 100 x109/L, internation-
al normalized ratio (INR) > 1.7 and activated partial 
thromboplastin time (APTT) > 40 s (23). Therefore, 
performance of these laboratory tests may be of-
ten necessary, especially when the suspicion of an 
underlying coagulopathy is particularly high. The 
AHA/ASA guidelines also recommend routine 
measurement of blood glucose in all patients with 
AIS (23). Persistent in-hospital hyperglycaemia dur-
ing the first 24 hours following an AIS is associated 
with worse outcome, thus making it reasonable to 
treat hyperglycaemia for achieving glucose values 
between 7.8-10.0 mmol/L and also establishing 
strict monitoring for preventing the possible onset 
of hypoglycaemia (23).
Integrated diagnostics in venous 
thromboembolism
The generic definition of venous thromboembo-
lism (VTE) encompasses the combination of two 
distinct but often associated clinical entities, i.e. 
deep vein thrombosis (DVT) and pulmonary em-
bolism (PE) (28). This condition represents perhaps 
the most paradigmatic example of how integrated 
diagnostics is necessary for making a timely and 
accurate diagnosis. Irrespective of the clinical 
guidelines that are used, the basic concept under-
neath is that a diagnosis of VTE necessitates a 
thoughtful integration of pre-test clinical probabil-
ity (based on history taking, signs and symptoms), 
results of laboratory testing and diagnostic imag-
ing (compression venous ultrasonography, com-
puted tomographic pulmonary angiography or 
lung scintigraphy or magnetic resonance angio-
graphy) (29-31). 
Although a vast array of biomarkers has been eval-
uated for diagnosing VTE, there is now universal 
agreement that D-dimer is the biochemical gold 
standard (32). Due to its extraordinarily high NPV, 
typically comprised between 97-99%, this test has 
been placed at the pinnacle of virtually all diag-
nostic algorithms, whereby a negative test result 
would allow to safely rule out an acute thrombotic 
episode with > 99% accuracy in low-risk patients 
(29-32). Likewise cardiac troponins for AMI, how-
ever, D-dimer is characterized by a very limited 
PPV (often < 50%), which would need additional 
elements for value interpretation (32). D-dimer 
values are consistently increased in a large num-
ber of relatively frequent physiological (e.g. older 
age, pregnancy) and pathological (e.g. infections, 
cancers) conditions, which can only be identified 
or excluded with diagnostic imaging (33). In this 
respect, integration of clinical, laboratory and ra-
diologic findings by means of information (expert) 
software systems was proven to be a reliable strat-
egy for improving diagnostic efficiency and re-
sources usage in different healthcare settings (34-
36).
The term “theranostics” (or “theragnostics”) is 
used to denote treatment strategies combining di-
agnostics with therapeutics (37). In brief, it com-
bines a diagnostic investigation that allows detect-
ing a certain pathology, with a therapeutic agent 
that is then contextually delivered at the exact site 
of disease. Among the various examples of ongo-
ing theranostics projects, the most representative 
of which is indeed precision medicine in cancer 
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therapy, thrombus-targeted fibrinolysis is emerg-
ing as a promising diagnostic and therapeutic op-
tion for patients with thrombotic disorders (38,39). 
Immunoconjugates or biocompatible nanoparti-
cles have been used for precisely localizing blood 
clots and for delivering targeted thrombolysis, 
which would ultimately increase the anti-throm-
botic effectiveness and decrease the risk of hem-
orrhagic events. The essential breakthrough of this 
diagnostic and therapeutic strategy is represented 
by the use of molecular imaging with different 
tracers (i.e. conventional anti-fibrin antibodies, fi-
brin beta chain antibodies, anti-D-dimer antibod-
ies, cyclic fibrin-binding peptides), and different 
imaging modalities (optical techniques, MRI, posi-
tron emission tomography (PET), single photon 
emission computed tomography (SPECT)), which 
help constructing an ideal bridge between tech-
nologies used in laboratory medicine and radiolo-
gy (40-42). Notably, a recent study showed that 
the use of high-resolution in vivo optical molecular 
imaging with near-infrared fluorescence (NIRF) fi-
brin-specific reporters permits to identify venous 
thrombi and dissect their vulnerability to fibrinoly-
sis, thus amplifying the diagnostic accuracy and 
therapeutic effectiveness (43).
Integrated diagnostics in cancer
Pathology has remained at the heart of cancer di-
agnostics for decades, since it has been the virtu-
ally unique branch of diagnostic medicine capable 
to identify malignant disease and defining the 
type of cancer, the stage and even the potential 
therapeutic vulnerability (44). The many progress-
es in our understanding of cancer biology (e.g. the 
discovery of genetic mutations and epigenetics 
determinants that drive cancer growth), coupled 
with notable technical advances, have considera-
bly mutated the background and the role of pa-
thologists in recent years, paving the way to devel-
opment of relatively innovative diagnostics fields, 
namely molecular diagnostics and genomic profil-
ing. Diagnostic imaging also plays an essential role 
in cancer care, since it participates to the initial di-
agnosis, and then contributes to surveillance, fol-
low-up and therapeutic monitoring (45). The third 
pivotal diagnostic branch, laboratory medicine, is 
also deeply involved in cancer diagnostics. Its cur-
rent contribution is minimal for the diagnosis, at 
least compared to that provided by pathology and 
radiology, since it is almost limited to assessment 
of a narrow number of biomarkers such as pros-
tate specific antigen (PSA) for prostate cancer 
screening, human papilloma virus (HPV) molecular 
diagnostics for the screening of cervical cancer, or 
faecal occult blood test (FOBT) for colorectal can-
cer screening (46-48). The vast majority of other 
molecular or phenotypic biomarkers that can be 
measured in routine clinical laboratories are in-
stead used for disease monitoring and for guiding 
prognostic and therapeutic decisions (49). Unlike 
other class of pathologies, integrated diagnostics 
is already a strong realism in cancer diagnostics, 
whereby almost each and every guideline or rec-
ommendation include a discrete number of labo-
ratory, pathology and radiology investigations 
(50). Digital pathology and large-scale computa-
tional analysis are also strongly emerging, and 
preliminary data shows that their combination 
with “radiomics” (i.e. the extraction of a large num-
ber of features from radiographic images using 
data-characterization algorithms) will enable sig-
nificant advances in diagnostic and prognostic ac-
curacy (51).
A similar “molecular revolution” that has involved 
pathology, and only marginally radiology, is now 
deeply engaging laboratory medicine (52). The 
analysis of aberrant pathways at molecular level is 
no longer limited to tissue samples obtained with 
invasive procedures (i.e. biopsies, surgery), but can 
now be made also in blood and in other biological 
fluids, by means of a much less invasive venipunc-
ture. The often misused or abused term “liquid bi-
opsy” is precisely defined by the US National Can-
cer Institute (NCI) as “a test done on a sample of 
blood to look for cancer cells from a tumour that 
are circulating in the blood or for pieces of DNA 
from tumour cells that are in the blood” (53). Ac-
cording to the NCI, liquid biopsy can hence be em-
ployed for early cancer detection, for defining the 
most appropriate therapy, for monitoring thera-
peutic response, and for early identifying malig-
nant recurrence. Future decision-making strate-
gies should hence leverage tissue- and blood-
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based biomarkers, as well as advanced imaging 
technologies (e.g. MRI, scintigraphy, PET) (54). The 
resulting combination of blood signatures, digital 
pathology and radiomics is the most efficient ap-
proach for more accurately diagnosing, character-
izing and treating cancer in the near future. Bio-
logically-driven interventional radiology and ther-
anostics hold great promises in the way a subset 
of cancer patients more likely to respond to target-
ed chemotherapies will be identified (50).
Integrated diagnostics in infectious diseases
Sepsis is the leading cause of death in patients 
with infectious diseases, accounting for up to 
270,000 deaths every year in the US (55). Respira-
tory infections, especially pneumonia, are the 
most frequent causes of systemic disease, and are 
responsible for the overall highest number of 
deaths (56). 
There are at least two foremost reasons that sup-
port the need of an accurate and timely diagnosis 
of sepsis. The first, and the most obvious, is 
straightforwardly summarized in the “It’s About 
TIME” mantra of the Sepsis alliance, which high-
lights that the prognosis of this condition is essen-
tially time-dependent (55). Rapid care, within the 
so-called “golden hours”, is hence crucial for pre-
venting disease transition into irreversible illness. 
The second important aspect is that a timely iden-
tification of responsible pathogens would prevent 
misuse or overuse of antibiotics, thus limiting the 
risk of antibiotic resistance, which has been recog-
nized by the WHO as a growing threat to global 
health (57).
There is now incontrovertible evidence that in vitro 
diagnostics plays an essential role in sepsis diag-
nostics, whereby it provides irreplaceable contri-
butions to screening (measuring procalcitonin, 
presepsin, C reactive protein and lactate), diagno-
sis (i.e. serology, blood cultures, nucleic acid analy-
sis), therapeutic monitoring (by longitudinal moni-
toring of procalcitonin), and establishing the prog-
nosis (by means of procalcitonin or with the Se-
quential Organ Failure Assessment (SOFA) score, 
which includes platelet count in combination with 
creatinine and total bilirubin concentration) (58-
60). Notably, the role of lactate is essential in pa-
tients with sepsis, since its concentration reflects 
tissue hypoperfusion and correlates with mortality 
(61).
The important role played by diagnostic imaging 
in sepsis patients has been emphasized by current 
guidelines for management of severe sepsis, 
whereby performance of imaging studies for con-
firming a potential source of infection is one of the 
three essential criteria that should be used for di-
agnosing sepsis along with clinical findings and re-
sults of microbiological testing (61). Although no 
specific radiologic signs may be present in sepsis 
patients, chest radiography is helpful for detecting 
pneumonia and ruling out other potential causes 
of pulmonary infiltrates (e.g. pulmonary hemor-
rhage, metastases, pleural effusions). Computed 
tomography scanning or MRI may also be used, 
since they are more sensitive than conventional ra-
diographies for detecting a vast array of possible 
sources of infections in chest, abdomen and other 
bodily districts (62).
Notably, the role of IT is also convincingly emerg-
ing in sepsis management. A recent study showed 
that promising results (i.e. lower mortality) have 
been obtained by implementing reinforcement 
learning for supporting sequential decision-mak-
ing problem in patients with sepsis (63). As for the 
previous cases, therefore, a path towards integrat-
ed diagnostics is now unavoidable in sepsis care 
(Figure 3).
Discussion
The current scenario of in vitro and in vivo diagnos-
tics has been effectively depicted by Lundström et 
al., using the “silo metaphor”, where laboratory 
medicine, pathology and radiology are three con-
ceptually separated disciplines sharing many com-
parable features, especially in terms of complex 
exploratory pathways (Figure 4) (64). Nevertheless, 
the considerable technological advancements and 
the extraordinary progresses occurred in our cur-
rent understanding of the biochemical-biological 
interplay characterizing many human diseases are 
now generating considerable multidisciplinary 
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Figure 3. The many domains of an integrated diagnostic approach in patients with sepsis. PCT – procalcitonin. CRP – C-reactive pro-
tein.
Figure 4. The “silo metaphor”, characterized by development of integrated diagnostics from convergence of laboratory medicine, 
pathology and radiology information.
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convergences, leading the way to new frontiers in 
integrated diagnostics. 
In the previous sections of this review, some para-
digmatic examples have been discussed, corre-
sponding to the three leading causes of world-
wide deaths, to provide an overview on the cur-
rent scenario and future perspectives of integrat-
ed diagnostics (Table 1). Cardiovascular disease, 
cancer and infectious disorders represent only a 
part of the many pathological conditions that 
may benefit from convergence and full integra-
tion of laboratory medicine, diagnostic imaging 
and pathology. Although it seems unavoidable 
that this process shall be further catalyzed and 
supported, there are some important obstacles 
that should be overcome, but there are also 
some possible solutions that can be identified 
(Table 2). 
Drawbacks Potential solutions
Infrastructure of information technology 
•	 Integrate exiting information systems
•	 Develop new integrated information systems
•	 Combine bioinformatics and imaging informatics
Costs •	 Health Technology Assessment
Enormous volume of different information
•	 Include (increase) expert comments in integrated reports
•	 Develop and use expert systems and neural networks
•	 Overcome cultural and political boundaries
•	 Create multidisciplinary teams
•	 Introduce integrated diagnostic algorithms
Table 2. Drawbacks and potential solution in integrated diagnostics
The IT infrastructure can perhaps be seen as one 
of the biggest drawbacks in integrated diagnos-
tics. The current laboratory, radiology, pathology 
and even hospital information systems have been 
constructed and developed independently, so 
that their connectivity is poor and functional inte-
gration is challenging, time-consuming and ex-
pensive (65). Although partial integration of data is 
occasionally feasible, especially within some hos-
pital or “regional” information systems, a new cul-
ture should be developed, characterized by devel-
opment of new software programs that will ena-
ble to collect, consolidate and integrate a large 
volume of different data within the same informa-
tion system, producing a fully integrated electron-
ic health report that will combine radiology, labo-
ratory and pathology data, enabling a more de-
tailed view of patient and care path (66). Conver-
gence of bioinformatics and imaging informatics 
will then be necessary for combining biology, im-
aging, computer science, information engineer-
ing, mathematics and statistics, to help analyzing 
and interpreting a huge amount of biological in-
formation (67).
Unfortunately, cost will be another major limiting 
step in development of integrated informatics 
platforms. Overcoming this hurdle will not be easy, 
since public funding in healthcare is substantially 
declining everywhere around the world, due to 
the residual effect of an unprecedented economic 
crisis (68). The use of Health Technology Assess-
ment (HTA) can be seen as a valuable solution for 
this problem, whereby the HTA definition per se 
encompasses a multi-professional and multidisci-
plinary assessment of cost-effectiveness of health 
technologies, based on active involvement of 
many different medical and diagnostic disciplines 
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(69). Clear demonstration that an earlier and more 
accurate diagnosis will determine a return of initial 
investment for implementing integrated diagnos-
tic platforms will lead the way to increased interest 
and funding.
The possible convergence of laboratory, patholo-
gy and imaging test results within the same medi-
cal report then implies that an enormous volume 
of different information will challenge the mind of 
healthcare professionals, especially of those who 
are directly in charge of the patient and will need 
to take the most appropriate medical actions, un-
ravelling many intricacies. Reinforcement of clini-
cal decision support through expert interpretation 
and counselling will become unavoidable (70). We 
should not forget that laboratory professionals act 
as managers of valuable clinical information and 
not as generators of raw numbers (71). In summa-
ry, laboratory professionals produce knowledge 
and the practice of laboratory stewardship, in-
tended as clinicians’ guidance towards appropri-
ate interpretation and use of laboratory informa-
tion, is a central part of our routine activity (72,73). 
Artificial intelligence and machine learning may 
also be used for this scope, with development of 
expert systems or neural networks capable to in-
tegrate different information and assist decision-
making abilities (74,75). All the available evidence, 
generated by heterogeneous diagnostic disci-
plines, shall then be combined into integrated di-
agnostic algorithms, which should carefully take 
into account advantages and the limitations of 
each test. This would inevitably require overcom-
ing cultural and sometimes political boundaries 
among healthcare professionals, for establishing 
or reinforcing the cooperation between scientific 
societies of different medical diagnostic disci-
plines, throughout creation of collaborative inter-
disciplinary teams at local, national and, prefera-
bly, even at a supranational levels (64). An essential 
issue in this efforts to provide integrated and high 
quality information is represented by harmoniza-
tion of clinical data. In particular, further efforts 
should be promoted to provide harmonization 
and standardization in laboratory medicine, not 
only in the analytical phase but also in all steps of 
the total testing process (76-78).
A final important issue concerns the education 
needed for using integrated diagnostics. Labora-
torians, pathologists and radiologists have faced 
and eagerly won many technical and practical 
challenges that have revolutionized their work 
during the past decades (37). Nevertheless, be-
coming an expert in integrated diagnostics will 
probably be one of the hardest challenges ever 
since, because biological and technical back-
ground will need to be enormously magnified. 
Two different scenarios may be portrayed, the for-
mer directed towards creation of the figure of a 
“Radio-Patho-Laboratorian”, who will work in a 
revolutionized “diagnostic room” where, potently 
supported by IT and artificial intelligence, this new 
healthcare professional will integrate laboratory, 
pathology and radiology data for providing a final 
interpretative support to the clinicians. In the sec-
ond scenario, instead, the daily work of laboratori-
an, pathologists and radiologists will remain al-
most unchanged, but an unified interface will be 
made available to clinicians, where patient data 
will be accessible in a more mineable form. We do 
not have a crystal ball, and we cannot predict the 
future. Neither we have a preference on either of 
these solutions. Only the future will tell which will 
be the dominant one.
In conclusion, integrated diagnostics can be con-
sidered one of the greatest opportunities for fu-
ture healthcare, since it would permit to deliver 
more patient-centric care, obtain better outcomes 
and ultimately decrease cost over time. The chance 
to merge different diagnostic modalities within a 
single medical record will also boost the develop-
ment of population-level databases, containing 
aggregated information on million of patients, 
and thus enabling to achieve a more holistic pic-
ture of many human diseases and developing 
more effective treatment. Additional efforts shall 
hence be made to foster the collaboration among 
different diagnostic disciplines, overcoming cul-
tural, political and technical boundaries, for devel-
oping the diagnostic discipline of the future. Will 
integrated diagnostics contribute to put an end to 
laboratory medicine, at least as we now know it?
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